In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance

被引：77

作者：

Bachmann, SP ^{[1
]}

Patterson, TF ^{[1
]}

López-Ribot, JL ^{[1
]}

机构：

[1] Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis,S Texas Ctr Biol Med, San Antonio, TX 78245 USA

来源：

JOURNAL OF CLINICAL MICROBIOLOGY | 2002年 / 40卷 / 06期

关键词：

D O I：

10.1128/JCM.40.6.2228-2230.2002

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Caspofungin inhibits the synthesis of 1,3-beta-D-glucan, a key step in fungal cell wall biosynthesis. Here we report on its potent in vitro activity (MIC at which 90% of the isolates tested are inhibited = 1 mug per ml of RPMI medium) against 32 Candida albicans fluconazole-susceptible and -resistant clinical isolates irrespective of the underlying resistance mechanism (alterations in ERG11 and/or upregulation of MDR and CDR genes encoding efflux pumps) and provide further evidence that caspofungin is not a substrate for multidrug transporters.

引用

收藏

页码：2228 / 2230

页数：3

相关论文

共 12 条

[1]

Barchiesi F, 1999, EUR J CLIN MICROBIOL, V18, P302

[2] In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) [J].

Bartizal, K ;

Gill, CJ ;

Abruzzo, GK ;

Flattery, AM ;

Kong, L ;

Scott, PM ;

Smith, JG ;

Leighton, CE ;

Bouffard, A ;

Dropinski, JF ;

Balkovec, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2326-2332

[3] Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. [J].

Marco, F ;

Pfaller, MA ;

Messer, SA ;

Jones, RN .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1998, 32 (01) :33-37

[4] Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis [J].

Müller, FMC ;

Weig, M ;

Peter, J ;

Walsh, TJ .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (02) :338-341

[5]

NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS-NCCLS, 1997, M27A NCCLS

[6]

Nelson PW, 1997, J MED VET MYCOL, V35, P285

[7] Simple method for detecting fluconazole-resistant yeasts with chromogenic agar [J].

Patterson, TF ;

Revankar, SG ;

Kirkpatrick, WR ;

Dib, O ;

Fothergill, AW ;

Redding, SW ;

Sutton, DA ;

Rinaldi, MG .

JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (07) :1794-1797

[8] Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients [J].

Perea, S ;

López-Ribot, JL ;

Kirkpatrick, WR ;

McAtee, RK ;

Santillán, RA ;

Martínez, M ;

Calabrese, D ;

Sanglard, D ;

Patterson, TF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2676-2684

[9] Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors [J].

Sanglard, D ;

Ischer, F ;

Monod, M ;

Bille, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2300-2305

[10] Cloning of Candida albicans genes conferring resistance to azole antifungal agents: Characterization of CDR2, a new multidrug ABC transporter gene [J].

Sanglard, D ;

Ischer, F ;

Monod, M ;

Bille, J .

MICROBIOLOGY-UK, 1997, 143 :405-416